Skip to content

Can I take potassium with lisinopril or spironolactone?

Short answer: Avoid with spironolactone, its label says, because severe hyperkalemia may result; use caution with lisinopril, whose label lists potassium supplements as a risk factor for high blood potassium.

Avoid with spironolactone, its label says; use caution with lisinopril. Both labels warn about high blood potassium (hyperkalemia). Potassium is on the lisinopril label (Zestril), which lists potassium supplements among the risk factors for hyperkalemia. The spironolactone (Aldactone) label says taking it with potassium supplementation "may lead to severe hyperkalemia" and that its patients "should be advised to avoid potassium supplements". The potassium chloride label adds: "Potentially fatal hyperkalemia can develop rapidly and be asymptomatic."

How well documented: On the drug’s label. The medicine’s FDA-approved label names this supplement, or the kind of product it is.

What's known

  • Lisinopril label. The Zestril (lisinopril) label says: "Serum potassium should be monitored periodically in patients receiving Zestril. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1)]." It also says: "Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient’s serum potassium frequently." Its patient counselling section says: "Hyperkalemia: Tell patients not to use salt substitutes containing potassium without consulting their physician." (Lisinopril label)
  • Spironolactone label. The Aldactone (spironolactone) label says: "ALDACTONE can cause hyperkalemia. This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions (7.1)]. Monitor serum potassium within 1 week of initiation or titration of ALDACTONE and regularly thereafter. More frequent monitoring may be needed when ALDACTONE is given with other drugs that cause hyperkalemia or in patients with impaired renal function." It also says: "Concomitant administration of ALDACTONE with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start ALDACTONE [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving ALDACTONE." And: "Patients who receive ALDACTONE should be advised to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes." (Spironolactone label)

What to do

  • The prescribing label for the potassium chloride tablet Klor-Con M says: 'Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest.' 'In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.' 'Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.' 'Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.' 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.' 'Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract.' 'Klor-Con M tablets should be discontinued immediately, and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.'
  • NIH's Office of Dietary Supplements (ODS) and the FDA say: People who have chronic kidney disease and those who use certain medications can develop abnormally high levels of potassium in their blood (a condition called hyperkalemia). Examples of these medications are angiotensin converting enzyme inhibitors, also known as ACE inhibitors, and potassium-sparing diuretics. Even in healthy people, getting too much potassium from supplements or salt substitutes can cause hyperkalemia if they consume so much potassium that their bodies can’t eliminate the excess. People at risk of hyperkalemia should talk to their health care providers about how much potassium they can safely get from food, beverages, and supplements. Diets higher in sodium are associated with an increased risk of developing high blood pressure, which is a major cause of stroke and heart disease.
  • NIH's Office of Dietary Supplements says: "Tell your doctor, pharmacist, and other health care providers about any dietary supplements and prescription or over-the-counter medicines you take." (NIH ODS)
  • Don't stop or change a prescribed medicine on your own.

Sources

  1. US National Library of Medicine. Zestril (lisinopril) tablets: prescribing information. DailyMed, revised January 2025. DailyMed
  2. US National Library of Medicine. Aldactone (spironolactone) tablets: prescribing information. DailyMed, revised November 2025. DailyMed
  3. US National Library of Medicine. Klor-Con M (potassium chloride) extended-release tablets: prescribing information. DailyMed, revised July 2025. DailyMed
  4. National Institutes of Health, Office of Dietary Supplements. Potassium: Fact Sheet for Consumers. Updated March 2021. NIH ODS
  5. US Food and Drug Administration. Sodium in Your Diet. Content current as of 5 March 2024. FDA